Mologen Ag

Marcos Timón-Jiménez

Burghardt Wittig

Laura Fuertes-López

The invention relates to using a combination of DNA-expression constructs for producing a drug for immunization againstinfections and a corresponding vaccine. The DNA-expression construct is also disclosed. According to said invention the immunogene P36 LACK is used in combination with athiol-specific antioxidant protein gene (TSA),kinetoplastid membrane protein 11 (KMP-11) and with aGP63 antigen for producing an immune response. Plasmides, preferably minimalist immunologically defined gene-expression constructs (MIDGE) can be used in the form of the DNA-expression construct. The inventive DNA-expression construct makes it possible to produce a vaccine for treatinginfectious diseases and is used in the form of a component of said vaccine.

[object Object]

Use of a combination of DNA expression constructs for the production of a remedy for the immunization against infections with leishmaniasis, as well as a corresponding vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. &#xa7;1.72(b). As stated in 37 C.F.R. &#xa7;1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading 'Abstract of the Disclosure.' The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.

Growing community of inventors

San Lorenzo de El Escorial, Spain

Marcos Timón-Jiménez